---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-25-000100"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2025-06-03T23:59:59+00:00"
generated_at: "2026-05-20T01:58:05.936139+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xeris unveils long-range strategy; targets ~$750M revenue by 2030

## Summary
- Reaffirms 2025 total revenue guidance of $260-$275M and commitment to adjusted EBITDA positivity.
- Expects total revenue of ~$750M by 2030, led by Recorlev growth.
- Anticipates Recorlev annual net revenue of ~$1B in 2035; XP-8121 peak net revenue $1-3B.
- Cites Recorlev revenue acceleration as inflection point to self-fund near- and long-term growth.
- Hosts first Analyst and Investor Day on June 3, 2025, in New York City.

## SEC filing metadata
- accession: 0001867096-25-000100
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2025-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709625000100/0001867096-25-000100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709625000100/xers-20250603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-25-000100
- JSON: https://secwatch.observer/filing/0001867096-25-000100.json
- Plain text: https://secwatch.observer/filing/0001867096-25-000100.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.